LadRx (OTCMKTS:CYTR) & MiNK Therapeutics (NASDAQ:INKT) Critical Contrast
LadRx (OTCMKTS:CYTR) & MiNK Therapeutics (NASDAQ:INKT) Critical Contrast
LadRx (OTCMKTS:CYTR – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.
LadRx（OTCMKTS: CYTR — 獲取評級）和 minK Therapeutics（納斯達克股票代碼：INKT — 獲取評級）都是小型醫療公司，但哪家企業更好？我們將根據兩家企業的風險實力、估值、股息、機構所有權、分析師建議、收益和盈利能力對比這兩家企業。
Earnings & Valuation
收益與估值
This table compares LadRx and MiNK Therapeutics' gross revenue, earnings per share and valuation.
該表比較了LadRx和minK Therapeutics的總收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LadRx | N/A | N/A | -$6.70 million | ($0.15) | N/A |
| MiNK Therapeutics | N/A | N/A | -$30.21 million | ($0.78) | -2.71 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股收益 | 市盈率 | |
| LadRx | 不適用 | 不適用 | -670 萬美元 | (0.15 美元) | 不適用 |
| MinK 療法 | 不適用 | 不適用 | -3,021 萬美元 | (0.78 美元) | -2.71 |
MiNK Therapeutics is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.
MinK Therapeutics的交易市盈率低於LadRx，這表明它目前是這兩隻股票中更實惠的一隻。
Profitability
盈利能力
This table compares LadRx and MiNK Therapeutics' net margins, return on equity and return on assets.
該表比較了LadRx和MinK Therapeutics的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| LadRx | N/A | -67.61% | -45.39% |
| MiNK Therapeutics | N/A | -168.94% | -78.30% |
| 淨利潤 | 股本回報率 | 資產回報率 | |
| LadRx | 不適用 | -67.61% | -45.39% |
| MinK 療法 | 不適用 | -168.94% | -78.30% |
Risk & Volatility
風險與波動性
LadRx has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of -0.66, suggesting that its stock price is 166% less volatile than the S&P 500.
LadRx的beta值爲1.96，這表明其股價的波動性比標準普爾500指數高96％。相比之下，minK Therapeutics的beta值爲-0.66，這表明其股價的波動性比標準普爾500指數低166％。
Analyst Recommendations
分析師建議
This is a breakdown of recent ratings and target prices for LadRx and MiNK Therapeutics, as provided by MarketBeat.
這是MarketBeat提供的LadRx和minK Therapeutics最近的評級和目標價格的明細。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LadRx | 0 | 0 | 0 | 0 | N/A |
| MiNK Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| 賣出評級 | 持有評級 | 買入評級 | 強勁的買入評級 | 評分分數 | |
| LadRx | 0 | 0 | 0 | 0 | 不適用 |
| MinK 療法 | 0 | 0 | 1 | 0 | 3.00 |
MiNK Therapeutics has a consensus target price of $7.00, indicating a potential upside of 231.75%.
MinK Therapeutics的共識目標價格爲7.00美元，表明潛在的上漲空間爲231.75％。
Institutional & Insider Ownership
機構和內部所有權
0.1% of LadRx shares are held by institutional investors. Comparatively, 1.4% of MiNK Therapeutics shares are held by institutional investors. 12.8% of LadRx shares are held by company insiders. Comparatively, 13.2% of MiNK Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
0.1% 的LadRx股票由機構投資者持有。相比之下，1.4％的MinK Therapeutics股票由機構投資者持有。12.8％的LadRx股票由公司內部人士持有。相比之下，MinK Therapeutics的股票中有13.2％由公司內部人士持有。強大的機構所有權表明大型基金經理、對沖基金和捐贈基金認爲一家公司有望實現長期增長。
Summary
摘要
LadRx beats MiNK Therapeutics on 6 of the 9 factors compared between the two stocks.
與兩隻股票相比，LadRx在9個因素中有6個擊敗了MinK Therapeutics。
About LadRx
關於 LadRx
(Get Rating)
（獲取評級）
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
LadRx Corporation是一家生物製藥公司，從事治療癌症患者的療法的發現和開發。該公司的先進藥物偶聯物阿多柔比星正在進行後期臨床試驗，是抗癌藥物多柔比星的一種版本。其臨床前療法包括針對癌症的鏈接活化藥物釋放的7、8、9和10。該公司前身爲CytrX Corporation，並於2022年9月更名爲LadrX Corporation。LadRx Corporation 成立於 1985 年，總部位於加利福尼亞州洛杉磯。
About MiNK Therapeutics
關於 MinK Therapeut
(Get Rating)
（獲取評級）
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
MinK Therapeutics, Inc. 是一家臨床階段的生物製藥公司，從事用於治療癌症和其他免疫介導疾病的同種異體、現成、不變的自然殺傷 T (inKT) 細胞療法的發現、開發和商業化。其候選產品是 AGENT-797，這是一種現成的同種異體藥物，用於 inkT 細胞療法和各種骨髓瘤疾病的治療，目前正處於 1 期臨床試驗。該公司前身爲AgentUS Therapeutics, Inc.。minK Therapeutics, Inc. 成立於2017年，總部位於紐約州紐約。minK Therapeutics, Inc. 是Agenus Inc.的子公司。
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 LadRx 的新聞和評級 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收LadrX及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。